ORLANDO — In patients with active or chronic thyroid eye disease, veligrotug improved symptoms of proptosis and diplopia and clinical activity score, according to 15-week results of the THRIVE and THRIVE-2 trials.
The 15-week results of the THRIVE trial in patients with active thyroid eye disease (TED) and the THRIVE-2 trial in patients with chronic TED were presented at the American Association of Clinical Endocrinology Annual Scientific and Clinical Conference.
As Healio previously reported, veligrotug (Viridian Therapeutics), a novel monoclonal antibody that is an insulin-like growth